Table 1 Baseline characteristics of patients on second-line antiretroviral regimens for more than 24 months at the Calmette Hospital/ESTHER cohort in Phnom Penh, Cambodia
Characteristics | Second-line cohort (n = 70) |
|---|---|
Male [n (%)] | 51 (72.8) |
Median age [years(IQR)*] | 40 (37-46) |
ARV* naïve before first line [n (%)] | 15 (21.4) |
PI naïve at switch [n (%)] | 70 (100.0) |
Initial first-line ARV treatment | |
d4T/3TC/EFV [n (%)] | 18 (26.1) |
d4T/3TC/NVP [n (%)] | 12 (17.1) |
AZT/3TC/NVP [n (%)] | 23 (33.3) |
AZT/3TC/EFV [n (%)] | 13 (18.8) |
Other first lines [n (%)] | 4 (5.8) |
Follow-up time on first-line HAART* (months) | |
Median (IQR) | 26.6 (15.2-29.4) |
Characteristics at switch | |
CD4 T-cell counts (n) | 70 |
Median nb cells/mm3 [n (IQR)] | 106 (42-168) |
Count <50 cells/mm3 [n (%)] | 20 (28.6) |
Median viral load (n = 65), [Log10 (IQR)] | 4.7 (3.1-5.4) |
Prescribed second-line ARV treatment | |
ddI/3TC/LPV/r [n (%)] | 46 (65.7) |
TDF/3TC/LPV/r [n (%)] | 5 (7.1) |
TDF/ddI/LPV/r [n (%)] | 7 (10.0) |
AZT/ddI/LPV/r [n (%)] | 6 (8.6) |
AZT/3TC/LPV/r[n (%)] | 2 (2.9) |
Other second lines [n (%)] | 4 (5.7) |
Follow-up time on second-line HAART (months) | |
Median (IQR) | 37.3 (34.2-39.0) |